Protein biomarkers for radiation exposure: Towards a proteomic approach as a new investigation tool

Annali dell'Istituto Superiore di Sanita

Volumn 45, Issue 3, 2009, Pages 278-286

  Guipaud, Olivier ^a   Benderitter, Marc ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE IRSN   (France)

Author keywords

Biomarker; Diagnostic; Ionising radiation; Prognostic; Proteomic

Indexed keywords

BIOLOGICAL MARKER; H2AFX PROTEIN, HUMAN; HISTONE; PROTEIN;

ARTICLE; DNA DAMAGE; GENETICS; HUMAN; NUCLEAR ACCIDENT; PHOSPHORYLATION; PROTEOMICS; RADIATION EXPOSURE; RADIOMETRY;

BIOLOGICAL MARKERS; DNA DAMAGE; HISTONES; HUMANS; PHOSPHORYLATION; PROTEINS; PROTEOMICS; RADIOACTIVE HAZARD RELEASE; RADIOMETRY;

EID: 70350336281     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Gorin NC, Fliedner TM, Gourmelon P, Ganser A, Meineke V, Sirohi B, et al. Consensus conference on European preparedness for haematological and other medical management of mass radiation accidents. Ann Hematol 2006;85: 671-9.
2. Fliedner TM, Friesecke I, Beyrer K (Ed.). Medical management of radiation accident: manual on the acute radiation syndrome. METREPOL (European Commission Concerted Action). Oxford: The British Institute of Radiology; 2001. p.1-66.
3. Barrett A, Jacobs A, Kohn J, Raymond J, Powles RL. Changes in serum amylase and its isoenzymes after whole body irradiation. Br Med J (Clin Res Ed) 1982;285:170-1.
4. Becciolini A, Giannardi G, Cionini L, Porciani S, Fallai C, Pirtoli L. Plasma amylase activity as a biochemical indicator of radiation injury to salivary glands. Acta Radiol Oncol 1984;23:9-14.
5. Bertho JM, Demarquay C, Frick J, Joubert C, Arenales S, Jacquet N, et al. Level of Flt3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia. Intern J Rad Biol 2001;77:703-12.
6. Crenn P, Coudray-Lucas C, Thuillier F, Cynober L, Messing B. Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. Gastroenterology 2000;119:1496-505.
7. Crenn P, Vahedi K, Lavergne-Slove A, Cynober L, Matuchansky C, Messing B. Plasma citrulline: A marker of enterocyte mass in villous atrophy-associated small bowel disease.Gastroenterology 2003;124:1210-9.
8. Junglee D, Katrak A, Mohiuddin J, Blacklock H, Prentice HG, Dandona P. Salivary amylase and pancreatic enzymes in serum after total body irradiation. Clin Chem 1986;32:609-10.
9. Hennequin C, Cosset JM, Cailleux PE, Girinsky T, Ganem G, Hubert D, et al. Blood amylase: a biological marker in irradiation accidents? Preliminary results obtained at the Gustave-Roussy Institut (GRI) and a literature review. Bull Cancer 1989;76:617-24.
10. Hofmann R, Schreiber GA, Willich N, Westhaus R, Bogl KW. Increased serum amylase in patients after radiotherapy as a probable bioindicator for radiation exposure. Strahlenther Onkol 1990;166:688-95.
11. Dubray B, Girinski T, Thames HD, Becciolini A, Porciani S, Hennequin C, et al. Post-irradiation hyperamylasemia as a biological dosimeter. Radiother Oncol 1992;24:21-6.
12. Akashi M, Hirama T, Tanosaki S, Kuroiwa N, Nakagawa K, Tsuji H, et al. Initial symptoms of acute radiation syndrome in the JCO criticality accident in Tokai-mura. J Rad Res 2001;42(Suppl):S157-S166.
13. Leslie MD, Dische S. Changes in serum and salivary amylase during radiotherapy for head and neck cancer: a comparison of conventionally fractionated radiotherapy with CHART. Radiother Oncol 1992;24:27-31.
14. Leslie MD, Dische S. The early changes in salivary gland function during and after radiotherapy given for head and neck cancer. Radiother Oncol 1994;30:26-32.
15. Becciolini A, Porciani S, Lanini A, Benucci A, Castagnoli A, Pupi A. Serum amylase and tissue polypeptide antigen as biochemical indicators of salivary gland injury during iodine-131 therapy. Eur J Nucl Med 1994;21:1121-5.
16. Becciolini A, Porciani S, Lanini A, Balzi M, Faraoni P. Proposal for biochemical dosimeter for prolonged space flights. Phys Med 2001;17 (Suppl.1):185-6.
17. Blakely WF, Ossetrova NI, Manglapus GL, Salter CA, Levine IH, Jackson WE, et al. Amylase and blood cell-count hematological radiation-injury biomarkers in a rhesus monkey radiation model-use of multiparameter and integrated biological dosimetry. Radiat Measur 2007;42:1164-70.
18. Lyman SD, Seaberg M, Hanna R, Zappone J, Brasel K, Abkowitz JL, et al. Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood 1995;86:4091-6.
19. Wodnar-Filipowicz A, Lyman SD, Gratwohl A, Tichelli A, Speck B, Nissen C. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood 1996;88:4493-9. (Pubitemid 26419132)
20. Siegel JA, Yeldell D, Goldenberg DM, Stabin MG, Sparks RB, Sharkey RM, et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med 2003;44:67-76.
21. Huchet A, Belkacemi Y, Frick J, Prat M, Muresan-Kloos I, Altan D, et al. Plasma Flt-3 ligand concentration correlated with radiation-induced bone marrow damage during local fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:508-15.
22. Bertho JM, Roy L, Souidi M, Benderitter M, Gueguen Y, Lataillade JJ, et al. New biological indicators to evaluate and monitor radiation-induced damage: an accident case report. Radiat Res 2008;169:543-50.
23. Bertho JM, Roy L, Souidi M, Benderitter M, Bey E, Racine R, et al. Initial evaluation and follow-up of acute radiation syndrome in two patients from the Dakar accident. Biomarkers 2009;14:94-102.
24. Lutgens LC, Deutz NE, Gueulette J, Cleutjens JP, Berger MP, Wouters BG, et al. Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiationinduced small bowel damage. Int J Radiat Oncol Biol Phys 2003;57:1067-74.
25. Lutgens L, Lambin P. Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma Citrulline. World J Gastroenterol 2007;13:3033-42.
26. Blijlevens NM, Lutgens LC, Schattenberg AV, Donnelly JP. Citrulline: a potentially simple quantitative marker of intestinal epithelial damage following myeloablative therapy. Bone Marrow Transplant 2004;34:193-6.
27. Lutgens LC, Deutz N, Granzier-Peeters M, Beets-Tan R, De Ruysscher D, Gueulette J, et al. Plasma citrulline concentration:a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. Int J Radiat Oncol Biol Phys 2004;60:275-85.
28. Lutgens LC, Blijlevens NM, Deutz NE, Donnelly JP, Lambin P, de Pauw BE. Monitoring myeloablative therapyinduced small bowel toxicity by serum citrulline concentration: a comparison with sugar permeability tests. Cancer 2005;103:191-9.
29. Vanclee A, Lutgens LC, Oving EB, Deutz NE, Gijbels MJ, Schouten HC, et al. Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant 2005;36:907-15.
30. Fuss JO, Cooper PK. DNA repair: dynamic defenders against cancer and aging. PLoS Biol 2006;e203.
31. Jeggo P, Lobrich M. Radiation-induced DNA damage responses. Radiat Prot Dosimetry 2006;122:124-7.
32. Huen MS, Chen J. The DNA damage response pathways: at the crossroad of protein modifications. Cell Res 2008;18:8-16.
33. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-31.
34. Fei P, El-Deiry WS. P53 and radiation responses. Oncogene 2003;22:5774-83.
35. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117-29.
36. Cavalcanti MB, de Jesus Amaral A, de Salazar EFT, Melo JA, de Faria Machado CG. p53 protein expression levels as bioindicator of individual exposure to ionising radiation by flow cytometry. Mol Cell Biochem 2008;308:127-31.
37. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
38. Kuo LJ, Yang LX. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo 2008;22:305-9.
39. Redon CE, Dickey JS, Bonner WM, Sedelnikova OA. Gamma-H2AX as a biomarker of DNA damage induced by ionising radiation in human peripheral blood lymphocytes and artificial skin. Advan Space Res 2009;43:1171-8.
40. Marchetti F, Coleman MA, Jones IM, Wyrobek AJ. Candidate protein biodosimeters of human exposure to ionizing radiation. Int J Radiation Biol 2006;82:605-39.
41. Donnadieu-Claraz M, Benderitter M, Joubert C, Voisin P. Biochemical indicators of whole-body gamma-radiation effects in the pig. Int J Radiation Biol 1999;75:165-74.
42. Wedlake L, McGough C, Hackett C, Thomas K, Blake P, Harrington K, et al. Can biological markers act as non-invasive, sensitive indicators of radiation-induced effects in the gastrointestinal mucosa? Aliment Pharmacol Terapeut 2008;27:980-7.
43. Roy L, Bertho JM, Souidi M, Vozenin MC, Voisin P, Benderitter M. Biochemical approach to prediction of multiple organ dysfunction syndrome. BJR Suppl 2005;27:146-51.
44. Desai N, Wu H, George K, Gonda SR, Cucinotta FA. Simultaneous measurement of multiple radiation-induced protein expression profiles using the Luminex(TM) system. Adv Space Res 2004;34:1362-7.
45. Nolan JP, Mandy FF. Suspension array technology: new tools for gene and protein analysis. Cell Molec Biol (Noisy-le-Grand, France). 2001;47:1241-56.
46. Nolan JP, Mandy F. Multiplexed and microparticle-based analyses: quantitative tools for the large-scale analysis of biological systems. Cytometry A 2006;69:318-25.
47. Sharma M, Halligan BD, Wakim BT, Savin VJ, Cohen ER, Moulder JE. The urine proteome as a biomarker of radiation injury. Proteomics - Clinical Applications 2008;2:1065-86.
48. Corthals GL, Wasinger VC, Hochstrasser DF, Sanchez JC. The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis 2000;21:1104-15.
49. Hong JH, Chiang CS, Campbell IL, Sun JR, Withers HR, McBride WH. Induction of acute phase gene expression by brain irradiation. Int J Radiat Oncol Biol Phys 1995;33:619-26.
50. Magic Z, Matic-Ivanovic S, Savic J, Poznanovic G. Ionising radiation-induced expression of the genes associated with the acute response to injury in the rat. Radiat Res 1995;143:187-93.
51. Trutic N, Magic Z, Urosevic N, Krtolica K. Acute-phase protein gene expression in rat liver following whole body X-irradiation or partial hepatectomy. Comp Biochem Physiol C Toxicol Pharmacol 2002;133:461-70.
52. Chen C, Lorimore SA, Evans CA, Whetton AD, Wright EG. A proteomic analysis of murine bone marrow and its response to ionising radiation. Proteomics 2005;5:4254-63.
53. Guipaud O, Holler V, Buard V, Tarlet G, Royer N, Vinh J, et al. Time-course analysis of mouse serum proteome changes following exposure of the skin to ionising radiation. Proteomics 2007;7:3992-4002.
54. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7.
55. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality. Nature reviews 2002;1:683-95.
56. Menard C, Johann D, Lowenthal M, Muanza T, Sproull M, Ross S, et al. Discovering clinical biomarkers of ionising radiation exposure with serum proteomic analysis. Cancer Res2006;66:1844-50.
57. Kong FM, Ao X, Wang L, Lawrence TS. The use of blood biomarkers to predict radiation lung toxicity: a potential strategy to individualize thoracic radiation therapy. Cancer Control 2008;15:140-50.